A citation-based method for searching scientific literature

Filippo Caraci, Gian Marco Leggio, Salvatore Salomone, Filippo Drago. F1000Res 2017
Times Cited: 14







List of co-cited articles
83 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.
Bryan L Roth, Douglas J Sheffler, Wesley K Kroeze. Nat Rev Drug Discov 2004
823
28

Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders.
Priya Bawa, Priyamvada Pradeep, Pradeep Kumar, Yahya E Choonara, Girish Modi, Viness Pillay. Drug Discov Today 2016
32
21

A perspective on multi-target drug discovery and design for complex diseases.
Rona R Ramsay, Marija R Popovic-Nikolic, Katarina Nikolic, Elisa Uliassi, Maria Laura Bolognesi. Clin Transl Med 2018
284
21


One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug.
Rebecca E Hughes, Katarina Nikolic, Rona R Ramsay. Front Neurosci 2016
55
14

Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
Mélanie Brignone, Françoise Diamand, Caroline Painchault, Shweta Takyar. Curr Med Res Opin 2016
17
14

Targeting the correct HDAC(s) to treat cognitive disorders.
André Fischer, Farahnaz Sananbenesi, Alison Mungenast, Li-Huei Tsai. Trends Pharmacol Sci 2010
278
14

Neuroinflammation in Alzheimer's disease.
Michael T Heneka, Monica J Carson, Joseph El Khoury, Gary E Landreth, Frederic Brosseron, Douglas L Feinstein, Andreas H Jacobs, Tony Wyss-Coray, Javier Vitorica, Richard M Ransohoff,[...]. Lancet Neurol 2015
14

Neurobiology of depression.
Eric J Nestler, Michel Barrot, Ralph J DiLeone, Amelia J Eisch, Stephen J Gold, Lisa M Monteggia. Neuron 2002
14

mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade.
Jason M Dwyer, Ashley E Lepack, Ronald S Duman. Int J Neuropsychopharmacol 2012
122
14

Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
14


The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.
Joseph R Moskal, Jeffrey S Burgdorf, Patric K Stanton, Roger A Kroes, John F Disterhoft, Ronald M Burch, M Amin Khan. Curr Neuropharmacol 2017
46
14

mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants.
Shigeyuki Chaki, Yukio Ago, Agnieszka Palucha-Paniewiera, Francesco Matrisciano, Andrzej Pilc. Neuropharmacology 2013
88
14

Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants.
Eiji Shimizu, Kenji Hashimoto, Naoe Okamura, Kaori Koike, Naoya Komatsu, Chikara Kumakiri, Michiko Nakazato, Hiroyuki Watanabe, Naoyuki Shinoda, Sin-ichi Okada,[...]. Biol Psychiatry 2003
812
14

TREK1 channel blockade induces an antidepressant-like response synergizing with 5-HT1A receptor signaling.
Dongqing Ye, Yang Li, Xiangrong Zhang, Fei Guo, Leiyu Geng, Qi Zhang, Zhijun Zhang. Eur Neuropsychopharmacol 2015
23
14

Experimental medication treatment approaches for depression.
D F Ionescu, G I Papakostas. Transl Psychiatry 2017
34
14

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy.
Mark J Millan, Yves Agid, Martin Brüne, Edward T Bullmore, Cameron S Carter, Nicola S Clayton, Richard Connor, Sabrina Davis, Bill Deakin, Robert J DeRubeis,[...]. Nat Rev Drug Discov 2012
678
14

A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
Michael E Thase, Atul R Mahableshwarkar, Marianne Dragheim, Henrik Loft, Eduard Vieta. Eur Neuropsychopharmacol 2016
78
14

Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype.
Catherine Heurteaux, Guillaume Lucas, Nicolas Guy, Malika El Yacoubi, Susanne Thümmler, Xiao-Dong Peng, Florence Noble, Nicolas Blondeau, Catherine Widmann, Marc Borsotto,[...]. Nat Neurosci 2006
274
14

New approaches to antidepressant drug discovery: beyond monoamines.
Olivier Berton, Eric J Nestler. Nat Rev Neurosci 2006
14

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Anita E Autry, Megumi Adachi, Elena Nosyreva, Elisa S Na, Maarten F Los, Peng-fei Cheng, Ege T Kavalali, Lisa M Monteggia. Nature 2011
14

Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study.
Roy H Perlis, Priya Moorjani, Jesen Fagerness, Shaun Purcell, Madhukar H Trivedi, Maurizio Fava, A John Rush, Jordan W Smoller. Neuropsychopharmacology 2008
71
14

Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
Maurizio Fava, Asli Memisoglu, Michael E Thase, J Alexander Bodkin, Madhukar H Trivedi, Marc de Somer, Yangchun Du, Richard Leigh-Pemberton, Lauren DiPetrillo, Bernard Silverman,[...]. Am J Psychiatry 2016
104
14

A key role for TGF-β1 in hippocampal synaptic plasticity and memory.
Filippo Caraci, Walter Gulisano, Chiara A Guida, Agata A R Impellizzeri, Filippo Drago, Daniela Puzzo, Agostino Palmeri. Sci Rep 2015
78
14

Fluoxetine Prevents Aβ1-42-Induced Toxicity via a Paracrine Signaling Mediated by Transforming-Growth-Factor-β1.
Filippo Caraci, Fabio Tascedda, Sara Merlo, Cristina Benatti, Simona F Spampinato, Antonio Munafò, Gian Marco Leggio, Ferdinando Nicoletti, Nicoletta Brunello, Filippo Drago,[...]. Front Pharmacol 2016
32
14

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
14


mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Nanxin Li, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Science 2010
14


Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
Nicolas D Iadarola, Mark J Niciu, Erica M Richards, Jennifer L Vande Voort, Elizabeth D Ballard, Nancy B Lundin, Allison C Nugent, Rodrigo Machado-Vieira, Carlos A Zarate. Ther Adv Chronic Dis 2015
128
14

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.
Harvey A Whiteford, Louisa Degenhardt, Jürgen Rehm, Amanda J Baxter, Alize J Ferrari, Holly E Erskine, Fiona J Charlson, Rosana E Norman, Abraham D Flaxman, Nicole Johns,[...]. Lancet 2013
14

A new nomenclature for classifying psychotropic drugs.
Filippo Caraci, Sam J Enna, Joseph Zohar, Giorgio Racagni, Gil Zalsman, Wim van den Brink, Siegfried Kasper, George F Koob, Carmine M Pariante, Pier Vincenzo Piazza,[...]. Br J Clin Pharmacol 2017
11
18

Dual or multi-targeting inhibitors: The next generation anticancer agents.
Nulgumnalli Manjunathaiah Raghavendra, Divya Pingili, Sundeep Kadasi, Akhila Mettu, S V U M Prasad. Eur J Med Chem 2018
86
14

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis.
Marc Krause, Yikang Zhu, Maximilian Huhn, Johannes Schneider-Thoma, Irene Bighelli, Adriani Nikolakopoulou, Stefan Leucht. Eur Arch Psychiatry Clin Neurosci 2018
79
14


Designed multiple ligands in metabolic disease research: from concept to platform.
W Gattrell, C Johnstone, S Patel, C Sambrook Smith, A Scheel, M Schindler. Drug Discov Today 2013
14
14

The importance of predictive biomarkers in oncology drug development.
Jan Trøst Jørgensen. Expert Rev Mol Diagn 2016
11
18

Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs.
Lin Tao, Feng Zhu, Feng Xu, Zhe Chen, Yu Yang Jiang, Yu Zong Chen. Pharmacol Res 2015
37
14

Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Agustin Casimiro-Garcia, Gary F Filzen, Declan Flynn, Christopher F Bigge, Jing Chen, Jo Ann Davis, Danette A Dudley, Jeremy J Edmunds, Nadia Esmaeil, Andrew Geyer,[...]. J Med Chem 2011
32
14

Can we rationally design promiscuous drugs?
Andrew L Hopkins, Jonathan S Mason, John P Overington. Curr Opin Struct Biol 2006
338
14

Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets.
Martin L Miller, Evan J Molinelli, Jayasree S Nair, Tahir Sheikh, Rita Samy, Xiaohong Jing, Qin He, Anil Korkut, Aimee M Crago, Samuel Singer,[...]. Sci Signal 2013
62
14

The physicochemical challenges of designing multiple ligands.
Richard Morphy, Zoran Rankovic. J Med Chem 2006
150
14



The role of fragment-based and computational methods in polypharmacology.
Giovanni Bottegoni, Angelo D Favia, Maurizio Recanatini, Andrea Cavalli. Drug Discov Today 2012
78
14

Multi-target therapeutics: when the whole is greater than the sum of the parts.
Grant R Zimmermann, Joseph Lehár, Curtis T Keith. Drug Discov Today 2007
690
14

From in silico target prediction to multi-target drug design: current databases, methods and applications.
Alexios Koutsoukas, Benjamin Simms, Johannes Kirchmair, Peter J Bond, Alan V Whitmore, Steven Zimmer, Malcolm P Young, Jeremy L Jenkins, Meir Glick, Robert C Glen,[...]. J Proteomics 2011
175
14

Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature.
Paramasivan Poornima, Jothi Dinesh Kumar, Qiaoli Zhao, Martina Blunder, Thomas Efferth. Pharmacol Res 2016
73
14

Designing multiple ligands - medicinal chemistry strategies and challenges.
Richard Morphy, Zoran Rankovic. Curr Pharm Des 2009
205
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.